Back to news

Repligen Falls as Investors Digest BioLife Solutions Deal Closing

Investivoq PriceTracker

Repligen Corporation (RGEN) is down 5.1% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver is the market’s reaction to Repligen closing its acquisition of BioLife Solutions on October 6, 2026. While the deal expands Repligen’s reach in cell therapy and adds a recurring consumables business, the stock decline suggests investors may be focusing on near-term dilution, integration risk, and execution questions rather than the longer-term strategic benefits.

Details:

  • Repligen announced today that it completed its previously announced acquisition of BioLife Solutions, turning BioLife into a wholly owned subsidiary.
  • When the transaction was announced in July, the company valued it at about $1.5 billion and structured it with both cash and Repligen stock, which can create dilution concerns for existing shareholders.
  • The merger terms called for BioLife holders to receive $11.25 in cash plus 0.1442 shares of Repligen common stock for each BioLife share, tying the transaction directly to Repligen’s equity.
  • Management has described BioLife as a high-margin, recurring-revenue business that strengthens Repligen’s position in the cell therapy market, so today’s weakness appears more tied to deal digestion than to a newly disclosed operating setback.

    • Sources:

    Repligen Corporation, SEC, GlobeNewswire

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    $RGEN Insider Trading Activity

    RGEN Insider Trades

    $RGEN insiders have traded $RGEN stock on the open market 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.

    Here’s a breakdown of recent trading of $RGEN stock by insiders over the last 6 months:

    • OLIVIER LOEILLOT (Chief Executive Officer) has made 0 purchases and 4 sales selling 17,719 shares for an estimated $2,993,346.
    • JASON K GARLAND (CFO) sold 530 shares for an estimated $79,500

    To track insider transactions, check out Investivoq's insider trading dashboard. You can access data on insider stock transactions through the Investivoq API insider transaction endpoint.

    Investivoq Alerts
    Receive RGEN Data Alerts
    Get market-moving data, filings, and signals for RGEN in real time.
    Sign Up

    $RGEN Hedge Fund Activity

    We have seen 250 institutional investors add shares of $RGEN stock to their portfolio, and 194 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    • PRICE T ROWE ASSOCIATES INC /MD/ removed 3,125,867 shares (-64.1%) from their portfolio in Q2 2026, for an estimated $426,493,293
    • T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 1,368,231 shares (+3153.5%) to their portfolio in Q2 2026, for an estimated $186,681,437
    • WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC added 788,571 shares (+inf%) to their portfolio in Q2 2026, for an estimated $107,592,627
    • AMERIPRISE FINANCIAL INC added 650,918 shares (+70.4%) to their portfolio in Q2 2026, for an estimated $88,811,251
    • BLACKROCK, INC. removed 608,116 shares (-10.1%) from their portfolio in Q2 2026, for an estimated $82,971,347
    • HOLOCENE ADVISORS, LP added 583,302 shares (+82.3%) to their portfolio in Q2 2026, for an estimated $79,585,724
    • VESTAL POINT CAPITAL, LP removed 525,000 shares (-56.8%) from their portfolio in Q2 2026, for an estimated $71,631,000

    To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

    $RGEN Analyst Ratings

    Wall Street analysts have issued reports on $RGEN in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

    Here are some recent analyst ratings:

    • JP Morgan issued a "Overweight" rating on 05/06/2026

    To track analyst ratings and price targets for $RGEN, check out Investivoq's $RGEN forecast page.

    $RGEN Price Targets

    Multiple analysts have issued price targets for $RGEN recently. We have seen 9 analysts offer price targets for $RGEN in the last 6 months, with a median target of $160.0.

    Here are some recent targets:

    • Robert Wasserman from Benchmark set a target price of $185.0 on 07/07/2026
    • Daniel Markowitz from Evercore ISI Group set a target price of $160.0 on 07/06/2026
    • Sidharth Sahoo from HSBC set a target price of $150.0 on 06/03/2026
    • Mike Polark from Wolfe Research set a target price of $145.0 on 06/02/2026
    • Dan Leonard from RBC Capital set a target price of $160.0 on 05/15/2026
    • Luke Sergott from Barclays set a target price of $160.0 on 05/06/2026
    • Casey Woodring from JP Morgan set a target price of $165.0 on 05/06/2026

    This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.